Parnax Lab Limited (PARNAXLAB) fundamentals
Parnax Lab Limited is a listed company, part of the Pharmaceuticals sector, listed on the NSE as PARNAXLAB (ISIN INE383L01019). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Parnax Lab Limited does
Parnax Lab Limited is an India-based holding company. The Company is principally engaged in the business activities of manufacturing and export of pharmaceutical formulations. The Company operates through the trading of the pharmaceuticals and medicinal products segment. It is engaged in developing and delivering huge volumes of oral formulations, such as cough expectorants, antacids, antihistamines, multi-vitamins, enzyme preparations, pediatric formulations, special formulations for geriatrics, viscous products, suspensions, and others. Its product portfolio consists of pharmaceuticals, cosmetics, herbal, and nutraceuticals. Its cosmetics products include antidruf gel, EVE fairness acne care night cream for acne skin, EVE fairness scrub, and others. The Company provides companies with the service of developing the drug through Contract Research and Manufacturing Services (C.R.A.M.S) or manufacturing collaborations. The Company’s subsidiary is Naxpar Pharma Private Limited.
Valuation and market data
| Last close | ₹127.00 |
|---|---|
| Market capitalisation | ₹146 crore |
| Enterprise value | ₹178 crore |
| P/E (TTM) | 0.00 |
| Price to book | 1.76 |
| Price to sales (TTM) | 0.57 |
| Book value per share | ₹72.35 |
| Dividend yield | 0.00% |
| Sector | Pharmaceuticals |
| Industry | — |
| Listed since | Mon Aug 17 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹9 crore | ₹1 crore | ₹1 crore | 0.00 |
| Mar 2025 | ₹8 crore | ₹2 crore | ₹1 crore | 1.21 |
| Mar 2024 | ₹8 crore | ₹2 crore | ₹2 crore | 1.59 |
| Mar 2023 | ₹8 crore | ₹2 crore | ₹1 crore | 1.09 |
| Mar 2022 | ₹7 crore | ₹1 crore | ₹1 crore | 0.64 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 72.3% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 27.7% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.